Physicians' choices in the first- and second-line management of type 2 diabetes in the Kingdom of Saudi Arabia.

Abstract

OBJECTIVES:

The DISCOVER study is a global, prospective, three- year- observational (non-interventional) study that was conducted in 37 countries throughout the world including Saudi Arabia and aimed to assess variations in treatment patterns and therapeutic outcomes in type 2 diabetic patients. The current manuscript is reporting data of DISCOVER study across different health sectors of various provinces in the Kingdom of Saudi Arabia.

METHODS:

In this study, 519 Saudi type 2 diabetics, non-insulin users, aged 18 years or older, initiating second line therapy, were selected from nine health institutes, in four out of five provinces in Saudi Arabia. Data was collected at baseline (initiation of 2nd line therapy) by the treating physician using an electronic case report form (eCRF) via a web-based data capture system. Each selected subject was asked to complete four self-administered questionnaires.

RESULTS:

The mean age of the studied population was 52.4 ± 11 years. Among the subjects selected from the nine medical centers, 55% were men, with almost 65% between the ages of 46 and 65 years. The oral agent used as 1st line in the majority of patients was metformin, prescribed in 89.2% of the study cohort. In the second line, sitagliptin was the most frequently used, at 61.8%. followed by gliclazide, glibenclamide, and glimepiride at 35.6%, 13.1%, and 12.7%, respectively.

CONCLUSION:

Metformin, with or without sulfonylureas, is the most commonly prescribed first-line treatment for patients with type 2 diabetes, managed either in governmental institutions, or in the private sector. The most common second line drugs were DPP4 inhibitors, mainly sitagliptin, followed by the third and second generation of sulfonylureas. Drug affordability was not an issue, since the vast majority of the patients received medication free of charge.

• Authors: Khalid Al-Rubeaan, Faisal A Bana, Fayez G Alruwaily, Eman Sheshah, Dhekra Alnaqeb, Awad M AlQahtani, Diaa Ewais, Nassr Al Juhani, Abdul-Hameed Hassan, Amira M Youssef
• Journal: Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society (Saudi Pharm J) Vol. 28 Issue 3 Pg. 329-337 (Mar 2020) ISSN: 1319-0164 [Print] Saudi Arabia
• PMID: 32194335 (Publication Type: Journal Article)
• Copyright: © 2020 The Author(s).